Resistance of Pseudomonas to ciprofloxacin: Implications for the treatment of malignant otitis externa

Journal of Laryngology and Otology

Volumn 121, Issue 2, 2007, Pages 118-123

  Bernstein, Jonathan M ^a   Holland, N J ^b   Porter, G C ^a   Maw, A R ^a  

^a ST MICHAEL'S HOSPITAL   (United Kingdom)

^b GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Ciprofloxacin; Drug resistance, microbial; Osteomyelitis; Otitis externa

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; CLOTRIMAZOLE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SOFRADEX;

AGED; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; EXTERNAL OTITIS; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OTORRHEA; OTOSCOPY; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; OTITIS EXTERNA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 33847259167     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0022215106002775     Document Type: Article

References (20)

1. Slattery WH, Brackmann DE. Skull base osteomyelitis: Malignant external otitis. Otorhinolaryngol Clin Nth Am 1996;29:795-806
2. Meyerhoff WL, Gates GA, Montalbo PJ. Pseudomonas mastoiditis. Laryngoscope 1977;87:483-92
3. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 1988;85:391-8
4. Meltzer PE, Kelemen G. Pyocutaneous osteomyelitis of the temporal bone, mandible, and zygoma. Laryngoscope 1959;169:1300-16
5. Chandler JR. Malignant external otitis. Laryngoscope 1968;78:1257-94
6. Hickey SA, Ford GR, O'Connor AF, Eykyn SJ, Sonksen PH. Treating malignant otitis with oral Ciprofloxacin. BMJ 1989;299:550-1
7. Levenson MJ, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). Laryngoscope 1991;101:821-4
8. Rubin Grandis JR, Branstetter BF 4th, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 2004;4:34-9
9. Berenholz L, Katzenell U, Harell M. Evolving resistant pseudomonas to Ciprofloxacin in malignant otitis externa. Laryngoscope 2002;112:1619-22
10. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005;55:535-41
11. Giamarellou H. Therapeutic guidelines for Pseudomonas aeruginosa infections. Int J Antimicrob Agents 2000;16:103-6
12. Lucente FE, Parisier SC. James R Chandler: Malignant external otitis [Classics from the laryngoscope]. Laryngoscope 1996;106:805-7
13. Subburaman N, Chaurasia MK. Skull base osteomyelitis interpreted as malignancy. J Laryngol Otol 1999;113:775-8
14. Okpala NC, Siraj QH, Nilssen E, Pringle M. Radiological and radionuclide investigation of malignant otitis externa. J Laryngol Otol 2005;119:71-5
15. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006;37(2):482-6
16. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-41
17. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003;57:677-701
18. D'Agata EMC. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a nine-year surveillance study. Infect Control Hosp Epidemiol 2004;25:842-6
19. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician 2001;63:2413-20
20. Lew DP, Waldvogel FA. Osteomyelitis. N Eng J Med 1997;336:999-1007